Alaska Permanent Fund Corp Sells 18 Shares of Chemed Co. (NYSE:CHE)

Alaska Permanent Fund Corp lowered its position in Chemed Co. (NYSE:CHE) by 2.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 706 shares of the company’s stock after selling 18 shares during the quarter. Alaska Permanent Fund Corp’s holdings in Chemed were worth $413,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC raised its position in shares of Chemed by 32.8% in the third quarter. SG Americas Securities LLC now owns 3,290 shares of the company’s stock valued at $1,710,000 after purchasing an additional 813 shares during the period. Golden State Equity Partners lifted its position in shares of Chemed by 29.4% during the third quarter. Golden State Equity Partners now owns 673 shares of the company’s stock worth $350,000 after acquiring an additional 153 shares in the last quarter. Trinity Street Asset Management LLP boosted its holdings in shares of Chemed by 3.0% in the third quarter. Trinity Street Asset Management LLP now owns 29,861 shares of the company’s stock worth $15,519,000 after acquiring an additional 863 shares during the period. Xponance Inc. grew its position in shares of Chemed by 1.8% in the third quarter. Xponance Inc. now owns 2,974 shares of the company’s stock valued at $1,546,000 after purchasing an additional 54 shares in the last quarter. Finally, Raymond James & Associates raised its stake in shares of Chemed by 2.7% during the 3rd quarter. Raymond James & Associates now owns 64,264 shares of the company’s stock valued at $33,398,000 after purchasing an additional 1,669 shares during the period. 95.85% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CHE. Oppenheimer lifted their target price on Chemed from $625.00 to $650.00 and gave the company an “outperform” rating in a report on Thursday, February 29th. Royal Bank of Canada lifted their price objective on Chemed from $604.00 to $712.00 and gave the company an “outperform” rating in a research note on Monday, March 4th. Finally, StockNews.com lowered Chemed from a “buy” rating to a “hold” rating in a research note on Friday.

Chemed Stock Performance

Chemed stock opened at $560.31 on Friday. Chemed Co. has a fifty-two week low of $492.84 and a fifty-two week high of $654.62. The stock has a market cap of $8.47 billion, a P/E ratio of 30.16, a price-to-earnings-growth ratio of 2.30 and a beta of 0.42. The firm’s fifty day moving average price is $623.76 and its 200-day moving average price is $590.54.

Chemed (NYSE:CHE) last issued its quarterly earnings results on Wednesday, April 24th. The company reported $4.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.09 by ($0.41). The firm had revenue of $589.23 million for the quarter, compared to the consensus estimate of $587.18 million. Chemed had a return on equity of 30.52% and a net margin of 12.36%. On average, analysts predict that Chemed Co. will post 21.99 earnings per share for the current year.

Chemed Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Monday, February 26th were issued a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.29%. The ex-dividend date of this dividend was Friday, February 23rd. Chemed’s dividend payout ratio is 8.61%.

Insider Activity

In other news, VP Brian C. Judkins sold 11,158 shares of the stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $645.00, for a total value of $7,196,910.00. Following the completion of the transaction, the vice president now owns 1,422 shares of the company’s stock, valued at approximately $917,190. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, VP Brian C. Judkins sold 11,158 shares of the business’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $645.00, for a total transaction of $7,196,910.00. Following the sale, the vice president now owns 1,422 shares in the company, valued at approximately $917,190. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Michael D. Witzeman sold 2,650 shares of the company’s stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $643.14, for a total value of $1,704,321.00. Following the completion of the sale, the chief financial officer now owns 2,882 shares in the company, valued at approximately $1,853,529.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,808 shares of company stock valued at $10,184,531. Corporate insiders own 3.32% of the company’s stock.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.